Abstract
A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.
Claims
-
A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human an antibiotic tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea, wherein the antibiotic tetracycline compound is selected from the group consisting of:
a 20 mg dose of doxycycline administered twice a day,
a 40 mg dose of doxycycline administered by sustained release over a 24 hour period,
a 38 mg dose of minocycline administered once a day,
a 60 mg dose of tetracycline administered once a day,
a 60 mg dose of tetracycline administered twice a day,
a 60 mg dose of tetracycline administered three times a day, and
a 60 mg dose of tetracycline administered four times a day,
wherein the antibiotic tetracycline compound is administered in an amount which results in a serum concentration which is 10-80% of the minimum antibiotic serum concentration.
- A method according to claim 1 further comprising observing a positive result in said simultaneous treatment of said ocular rosacea and acne rosacea.
- A method according to claim 2 further comprising continuing treatment.
- A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound administered in an amount which is 10-80% of the antibiotic amount.
- A method according to claim 1, wherein said tetracycline compound is doxycycline administered in an amount which results in a serum concentration which is 1.0 μg/ml.
- A method according to claim 1, wherein said tetracycline compound is minocycline administered in an amount which results in a serum concentration which is 0.8 μg/ml.
- A method according to claim 1, wherein said tetracycline compound is tetracycline administered in an amount which results in a serum concentration which is 0.5 μg/ml.
- A method according to claim 1, wherein said antibiotic tetracycline compound is doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts thereof.
- A method according to claim 8, wherein said antibiotic tetracycline compound is doxycycline.
- A method according to claim 9, wherein said doxycycline is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.
- A method according to claim 9, wherein said doxycycline is administered in an amount of 20 milligrams once daily.
- A method according to claim 1, wherein said tetracycline compound has a photoirritancy factor of less than the photoirritancy factor of doxycycline.
- A method according to claim 1, wherein said tetracycline compound has a photoirritancy factor from about one to about two.
- A method according to claim 1, wherein said tetracycline compound has a photoirritancy factor from about 1.0 to about 1.2.
- A method according to claim 1, wherein said systemic administration is oral administration, intravenous injection, intramuscular injection, subcutaneous administration, transdermal administration or intranasal administration.
Owners (US)
-
Galderma Laboratories Inc
(Jul 29 2008)
Explore more patents:
Applicants
-
Ashley Robert A
Explore more patents:
-
Galderma Lab Inc
Explore more patents:
Inventors
CPC Classifications
-
A61K31/65
Explore more patents:
IPC Classifications
Download PDF
Document Preview
Document History
- Publication: Jun 5, 2012
-
Application:
Nov 16, 2005
US 28098705 A
-
Priority:
Nov 16, 2005
US 28098705 A
-
Priority:
Apr 16, 2003
US 41480803 A